Comprehensive bioinformatics and in vitro studies reveal the carcinogenic role and molecular basis of endocrine disruptors in prostate cancer
Abstract
Background In recent years, growing attention has been paid to the carcinogenicity of endocrine disruptors (EDs). However, their relationship with prostate cancer (PCa) remains unclear. This study investigates the association between EDs and PCa to identify key genes that may bridge this relationship. Methods The ADME properties and carcinogenicity of the selected endocrine-disrupting chemicals EDs were predicted using the ADMETlab 3.0 and ProTox 3.0 platforms, respectively. Potential target genes related to EDs and PCa were obtained by integrating multiple public databases. A protein-protein interaction (PPI) network of the overlapping genes was constructed and visualized, followed by GO and KEGG enrichment analyses to explore their potential biological mechanisms. From 101 machine learning algorithm combinations, the most relevant key genes for PCa progression were screened. Molecular docking analysis was used to evaluate the binding properties between ED compounds and key targets. Pan-cancer analysis was employed to examine the general role of key genes across multiple cancer types. The Comparative Toxicogenomics Database (CTD) was used to identify natural active products potentially targeting the core genes. Finally, in vitro cell experiments were conducted to validate the effects of EDs on PCa cells and the intervention effects of related natural products. Results Initially, predictions from the ADMETlab 3.0 and ProTox 3.0 platforms indicated significant in vivo…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.